Virtu Financial LLC A Tyr Pharma Inc Transaction History

Virtu Financial LLC

$1.82 Billion
Q3 2024

A detailed history of Virtu Financial LLC transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Virtu Financial LLC holds 29,017 shares of LIFE stock, worth $53,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,017

Previous 27,966 3.76%

Holding current value

$53,971

Previous $44,000 15.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 20, 2024	BUY	$1.51 - $2.24 $1,587 - $2,354	1,051 Added 3.76%	29,017 $51,000
Q2 2024 Aug 09, 2024	BUY	$0.0 - $2.07 $0 - $57,889	27,966 New	27,966 $44,000
Q4 2023 Feb 26, 2024	BUY	$1.11 - $1.51 $14,149 - $19,247	12,747 Added 93.3%	26,409 $37,000
Q3 2023 Nov 14, 2023	BUY	$1.55 - $2.23 $21,176 - $30,466	13,662 New	13,662 $22,000
Q2 2022 Aug 09, 2022	SELL	$2.63 - $5.61 $739 - $1,576	-281 Reduced 2.14%	12,845 $36,000
Q1 2022 May 17, 2022	BUY	$4.75 - $7.54 $62,348 - $98,970	13,126 New	13,126 $70,000
Q4 2021 Feb 17, 2022	SELL	$7.29 - $9.5 $1.05 Million - $1.36 Million	-143,677 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.22 - $12.48 $606,316 - $1.79 Million	143,677 New	143,677 $1.31 Million
Q1 2021 May 19, 2021	SELL	$3.53 - $8.06 $97,908 - $223,552	-27,736 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$3.07 - $4.66 $85,149 - $129,249	27,736 New	27,736 $108,000
Q2 2020 Aug 07, 2020	SELL	$2.55 - $4.58 $28,516 - $51,218	-11,183 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$3.03 - $4.83 $33,884 - $54,013	11,183 New	11,183 $47,000

Others Institutions Holding LIFE

# of Institutions

Shares Held

37.1M

Call Options Held

30.2K

Put Options Held

3.1K

View Full List

About aTYR PHARMA INC

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $53.2M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

More about LIFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.

Account

Virtu Financial LLC A Tyr Pharma Inc Transaction History